RT Journal Article
SR Electronic
T1 Measuring brain integrity using MRI: a novel biomarker for Alzheimer’s disease using T2 relaxometry
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20100339
DO 10.1101/2020.05.13.20100339
A1 Wearn, Alfie R.
A1 Nurdal, Volkan
A1 Saunders-Jennings, Esther
A1 Knight, Michael J.
A1 Isotalus, Hanna K.
A1 Dillon, Serena
A1 Tsivos, Demitra
A1 Kauppinen, Risto A.
A1 Coulthard, Elizabeth J.
YR 2020
UL http://medrxiv.org/content/early/2020/05/16/2020.05.13.20100339.abstract
AB Early Alzheimer’s disease diagnosis is vital for development of disease-modifying therapies. Prior to significant loss of brain tissue, several microstructural changes take place as a result of Alzheimer’s pathology. These include deposition of amyloid, tau and iron, as well as altered water homeostasis in tissue and some cell death. T2 relaxation time, a quantitative MRI measure, is sensitive to these changes and may be a useful non-invasive, early marker of tissue integrity which could predict conversion to dementia. The different factors that affect T2 may cause it to increase, as in the case of free water, or decrease, as in the case of iron, amyloid and tau. Thus, tissue affected by early Alzheimer’s disease could become more heterogeneous yet show no change in average T2. We hypothesise that T2 heterogeneity in regions affected early in Alzheimer’s disease (hippocampus and thalamus) may present a sensitive early marker of microstructural changes in Alzheimer’s disease.In this cohort study, we tested 97 healthy older controls, 49 people with mild cognitive impairment (MCI) and 10 with a diagnosis of Alzheimer’s disease. All participants underwent structural MRI including multi-echo sequence for assessing quantitative T2. Cognitive change over one year was assessed in participants with MCI. Hippocampus and thalamus were automatically masked using ASHS and Freesurfer, respectively. T2 distributions were modelled using log-logistic distribution giving measures of log-median value (midpoint; T2μ) and distribution width (heterogeneity; T2σ).We show an increase in heterogeneity (T2σ; p<.0001) in MCI compared to healthy controls, which was not seen with midpoint (T2μ; p=.149) in the hippocampus and thalamus. Hippocampal T2 heterogeneity predicted cognitive decline over one year in MCI participants (p=.018), but midpoint (p=.132) and volume (p=.315) did not. Age affects T2, but the effects described here are significant even after correcting for age.We show that T2 heterogeneity can identify subtle changes in microstructural integrity of brain tissue in prodromal Alzheimer’s disease. We describe a new model that takes into account the competing effects of factors that both increase and decrease T2. These two opposing forces act in opposition and mean that previous human literature focusing on midpoint T2 has obscured the true potential of T2 as an early marker of Alzheimer’s disease. In fact, T2 heterogeneity outperforms midpoint and volumetry in predicting cognitive decline in those with MCI. We propose that T2 heterogeneity reflects microstructural integrity with potential to be a widely used early biomarker of Alzheimer’s disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Alzheimer's Research UK, BRACE and Wellcome (109067/Z/15/AI).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from corresponding authors upon request. ApBeta-amyloidACE-IIIAddenbrooke’s cognitive examination version 3ADAlzheimer’s diseaseAICAkaike Information CriteriaHCHealthy controlMCIMild cognitive impairmentMoCAMontreal cognitive assessmentMPRAGEMagnetization-prepared rapid gradient echoT2μT2 midpoint model parameterT2σT2 distribution width model parameter (heterogeneity)TSETurbo spin-echoYOEYears of education